Product Name:
MARK1-pT215
Product Number:
ab-pk694
Target Full Name: MAP/microtubule affinity-regulating protein-serine kinase 1
Target Alias: KIAA1477; MAP/microtubule affinity-regulating kinase 1; MARK
Product Type Specific: MARK1 protein kinase phosphosite-specific antibody
Antibody Code: PK694
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T215
Protein UniProt: Q9P0L2
Protein SigNET: MARK1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human MARK1 sequence peptide Cat. No.: PE-04AAT95
Antibody Immunogen Sequence: NKLD(pT)F(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues K212 to G218. This is the major in vivo phosphorylation site in MARK1. T215 phosphorylation stimulates phosphotransferase activity. This phosphosite is located in the kinase activation loop between catalytic subdomains VII and VIII. MARK1 is known to be phosphorylated at this site in vitro by LKB1 (STK11), and TAO1 (TAOK1/MAP3K16).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Rat | Mouse | Platypus | Frog | Nematode worm.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 85-90 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: Strong 46K cross-reactive protein (Nim1, LKB and ATP6V1C2 are candidates).
Related Product 1: MARK1 (212-218) pT215 antibody blocking peptide (Cat. No.: PE-04AAT95)
Related Product 2: MARK1-ANT pan-specific antibody (Cat. No.: AB-NK098-2)
Related Product 3: MARK1-pT215 phosphosite-specific antibody (Cat. No.: AB-PK695)
Related Product 4: Chk1Selectide kinase substrate peptide (Cat. No.: PE-01BGS90)
Related Product 5: MARK2-ANT pan-specific antibody (Cat. No.: AB-NK275-1)
Related Product 6: MARK2-BCT pan-specific antibody (Cat. No.: AB-NK275-2)
Related Product 7: MARK3-ANT pan-specific antibody (Cat. No.: AB-NK276-1)
Related Product 8: MARK3-BCT pan-specific antibody (Cat. No.: AB-NK276-2)
Related Product 9: MARK3-pT507 phosphosite-specific antibody (Cat. No.: AB-PK697)
Related Product 10: MARK4-ANT pan-specific antibody (Cat. No.: AB-NK277-1)
Scientific Background: MARK1 (Microtubule affinity-regulating kinase 1) is a 125 kDa protein-serine/threonine kinase that is is a member of the CAMK group of protein kinases in the CAMKL family, and MARK subfamily. It mediates control of cell polarity and microtubule function. It features a catalytic kinase domain, a ubiquitin-associated (UBA) domain, and a carboxy-terminal kinase-associated (KA1) domain. The protein's activity is regulated by its KA1 domain, which mediates autoinhibition and phospholipid activation. It is activated by phosphorylation on Thr-215 by STK11 in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39. MARK1 phosphorylates tau, microtubule-associated proteins MAP2, and MAP4 in their KXGS repeat motifs, causing their detachment from microtubules and triggering microtubule disruption, affecting cytoskeletal dynamics. It acts as a positive regulator of the Wnt signaling pathway, mediating phosphorylation of dishevelled proteins (DVL1, DVL2, and/or DVL3). This kinase is highly expressed and widely distributed in most tested human tissues except apparently in the brain and spinal cord. Gene mutation studies performed in mice revealed that after targeted disruption of the MARK1 gene, the mice lacked the ability to drink, and displayed hind leg motor dysfunction. Genetic variations in MARK1 have been correlated with susceptibility to autism. MARK1 is over-expressed in the prefrontal cortex of autism patients and affects the function of cortical dendrites. It is associated with Tau-related diseases (tauopathies) and Alzheimer's (paired helical filaments) due to its role in phosphorylation. MARK1 has also been linked with the development of gastric adenocarcinomas and ovarian serous carcinomas. This description may include information annotated by UniProt and/or Google AI.